1-(tert-butyl) 4-((1s,5s)-5-((chlorocarbonyl)oxy)cyclooctyl) piperazine-1,4-dicarboxylate | 178972-37-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(tert-butyl) 4-((1s,5s)-5-((chlorocarbonyl)oxy)cyclooctyl) piperazine-1,4-dicarboxylate
• CAS: 178972-37-7
• 化学式: C₁₉H₃₁ClN₂O₆
• 分子量: 418.918
• InChiKey: YLJDZOVMQWFLQF-GASCZTMLSA-N

物化性质

• 沸点：
  495.8±40.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.14
• 重原子数：
  28.0
• 可旋转键数：
  2.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  85.38
• 氢给体数：
  0.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  1-(tert-butyl) 4-((1s,5s)-5-((chlorocarbonyl)oxy)cyclooctyl) piperazine-1,4-dicarboxylate 在 盐酸 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-[4-(1-tert-Butoxycarbonyl-piperidin-4-yl)-butyryl]-piperazine-1-carboxylic acid 5-{4-[(4-carbamimidoyl-benzoylamino)-methyl]-piperidine-1-carbonyloxy}-cyclooctyl ester
  参考文献：
  名称：

  Dibasic Inhibitors of Human Mast Cell Tryptase. Part 3: Identification of a Series of Potent and Selective Inhibitors Containing the Benzamidine Functionality

  摘要：

  A survey of charged groups and linkers for a series of symmetrical and unsymmetrical dibasic inhibitors is described. leading to several classes of potent and selective inhibitors. In particular. the benzamidine functionality was identified as the most potent charged group investigated. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00254-2
• 作为产物：
  描述：

  cyclooctane-1,5-diol 在 potassium carbonate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲苯 、 乙腈 为溶剂， 生成 1-(tert-butyl) 4-((1s,5s)-5-((chlorocarbonyl)oxy)cyclooctyl) piperazine-1,4-dicarboxylate
  参考文献：
  名称：

  Dibasic inhibitors of human mast cell tryptase. Part 2: Structure–activity relationships and requirements for potent activity

  摘要：

  Detailed structure-activity relationships (SARs) for a series of dibasic human tryptase inhibitors are presented. The structural requirements for potent inhibitory activity are remarkably broad with a range of core template modifications being well tolerated. Optimized inhibitors demonstrate potent anti-asthmatic activity in a sheep model of allergic asthma. APC-2059, a dibasic tryptase inhibitor with subnanomolar activity, has been advanced to phase II clinical trials for the treatment of both psoriasis and ulcerative colitis. (C) 2000 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(00)00485-6

文献信息

• [EN] COMPOSITIONS AND METHODS FOR TREATING MAST-CELL INFLAMMATORY CONDITION<br/>[FR] COMPOSITIONS ET PROCEDES DE TRAITEMENT DE MALADIES INFLAMMATOIRES PROVOQUEES PAR LES MASTOCYTES
  申请人：ARRIS PHARMACEUTICAL CORPORATION

  公开号：WO1996009297A1

  公开（公告）日：1996-03-28

  (EN) Novel compounds, compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders are described. The compounds, compositions and methods are effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, as well as other types of immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis and inflammatory bowel disease, various dermatological conditions, as well as certain viral conditions. The compounds comprise potent and selective inhibitors of the mast cell protease tryptase. The compositions for treating these conditions include oral, inhalant, topical and parenteral preparations as well as devices comprising such preparations.(FR) L'invention concerne de nouveaux composés, compositions et procédés efficaces pour la prévention et le traitement de maladies inflammatoires provoquées par les mastocytes. Ces composés, compositions et procédés sont efficaces pour la prévention et le traitement de maladies inflammatoires associées aux voies respiratoires, telles que l'asthme et la rhinite allergique, ainsi que d'autres types de maladies inflammatoires d'origine immune, telles que la polyarthrite rhumatoïde, la conjonctivite et les inflammations intestinales, différentes maladies dermatologiques, ainsi que certaines maladies virales. Les composés comprennent des inhibiteurs puissants et sélectifs de la protéase tryptase des mastocytes. Les compositions de traitement de ces maladies comprennent des préparations s'administrant par voie orale, nasale, locale ou parentérale, ainsi que des systèmes contenant lesdites préparations.

  新型化合物、组合物和方法被描述为有效预防和治疗由肥大细胞介导的炎症性疾病。这些化合物、组合物和方法对于预防和治疗与呼吸道相关的炎症性疾病，如哮喘和过敏性鼻炎，以及其他类型的免疫介导的炎症性疾病，如类风湿性关节炎、结膜炎和炎症性肠病、各种皮肤状况以及某些病毒性疾病都有效。这些化合物包括肥大细胞蛋白酶酶抑制剂，具有强效和选择性。治疗这些疾病的组合物包括口服、吸入、局部和静脉制剂以及包含这些制剂的设备。
• COMPOSITIONS AND METHODS FOR TREATING MAST-CELL INFLAMMATORY CONDITION
  申请人：ARRIS PHARMACEUTICAL CORPORATION

  公开号：EP0782571A1

  公开（公告）日：1997-07-09
• US6022969A
  申请人：——

  公开号：US6022969A

  公开（公告）日：2000-02-08
• US6211228B1
  申请人：——

  公开号：US6211228B1

  公开（公告）日：2001-04-03
• Dibasic Inhibitors of Human Mast Cell Tryptase. Part 3: Identification of a Series of Potent and Selective Inhibitors Containing the Benzamidine Functionality
  作者：Jeffrey M. Dener、Kenneth D. Rice、William S. Newcomb、Vivian R. Wang、Wendy B. Young、Anthony R. Gangloff、Elaine Y.-L. Kuo、Lynne Cregar、Daun Putnam、Martin Wong

  DOI：10.1016/s0960-894x(01)00254-2

  日期：2001.7

  A survey of charged groups and linkers for a series of symmetrical and unsymmetrical dibasic inhibitors is described. leading to several classes of potent and selective inhibitors. In particular. the benzamidine functionality was identified as the most potent charged group investigated. (C) 2001 Elsevier Science Ltd. All rights reserved.